Table 3.
Logistic regression analyses using signature scores to predict CDAI nonremission at 6 months of biologic therapy
| Drug | Gene set | Univariate analysis | Multivariate analysisa | ||||
|---|---|---|---|---|---|---|---|
| OR | 95 % CI | p Value | OR | 95 % CI | p Value | ||
| IFX | |||||||
| Inflammasomes | 1.81 | (1.23–2.78) | 0.00382 | 1.72 | (1.14–2.71) | 0.00873 | |
| TCZ | |||||||
| Specific CD19 (Watkins et al., 2009 [15]) | 0.24 | (0.05–0.72) | 0.02677 | 0.16 | (0.02–0.71) | 0.01327 | |
| ABT | |||||||
| Elongation arrest and recovery | 5.73 | (1.47–49.11) | 0.04488 | 6.85 | (1.09–4426.71) | 0.03309 | |
| Specific CD56 (Watkins et al., 2009 [15]) | 3.25 | (1.18–12.43) | 0.04179 | 6.46 | (1.60–88.39) | 0.00388 | |
Abbreviations: CDAI clinical disease activity index, IFX infliximab, TCZ tocilizumab, ABT abatacept, OR odds ratio, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, MTX methotrexate, ESR erythrocyte sedimentation rate
aMultivariate analysis adjusted for significant (p < 0.1) variables as in Additional file 4 (IFX: female, concomitant csDMARD use [except MTX], ESR, CDAI; TCZ: disease duration, CDAI; ABT: disease duration, concomitant steroid use)